Form 4: STERIS Executive Exercises Options, Sells Shares

STERIS plc Senior VP John Zangerle exercised stock options and subsequently sold an equal number of ordinary shares on November 11, 2025.

Summary

• John Adam Zangerle, Senior VP, General Counsel, and Secretary of STERIS plc, engaged in a transaction on November 11, 2025.
• The transaction involved the exercise of an employee stock option to acquire 15,000 ordinary shares at an exercise price of $69.72 per share.
• Concurrently, Mr. Zangerle disposed of 15,000 ordinary shares at a weighted average sale price of $265.14 per share, with individual sales ranging from $265.00 to $265.95.
• Following these transactions, Mr. Zangerle beneficially owns 33,669 ordinary shares directly.
• Of the beneficially owned shares, 8,511 are restricted, with vesting scheduled between June 1, 2026, and June 5, 2028.
• The option exercised was fully vested and originated from the company's redomiciliation to Ireland in March 2019.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a pre-planned transaction under a 10b5-1 plan, which is a common practice for executives managing their compensation and liquidity. The significant profit realized by the executive also reflects positively on the company's stock performance.

Positives

• The executive realized a significant gain from the exercise of options and subsequent sale, reflecting strong stock performance for STERIS plc.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled and non-discretionary sale, which can mitigate concerns about opportunistic insider selling.

Negatives

• An insider selling shares, even if planned, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in 'skin in the game'.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape for STERIS plc.

Stakeholder Impact

• Shareholders may note the executive's decision to sell shares, though the pre-planned nature under Rule 10b5-1(c) typically reduces negative interpretations.
• The transaction demonstrates the value realized by executives through equity compensation, which can be a positive signal for employee retention and motivation.

Next Steps

• Lapse of restrictions on remaining 8,511 restricted ordinary shares on various dates between June 1, 2026, and June 5, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale) by a senior executive. While the executive realized a substantial profit, which is positive for the individual, the transaction itself does not provide new fundamental information about STERIS plc's operational performance, strategic direction, or future prospects that would warrant a change in investment recommendation. It's a common event for executives to manage their equity compensation. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

STERIS plc, STE, Insider Transaction, Form 4, Stock Option Exercise, Share Sale, Executive Compensation, Beneficial Ownership, Rule 10b5-1